These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 27628534)

  • 1. Four-Factor Prothrombin Complex Concentrate for Coagulopathy Reversal in Patients With Liver Disease.
    Huang WT; Cang WC; Derry KL; Lane JR; von Drygalski A
    Clin Appl Thromb Hemost; 2017 Nov; 23(8):1028-1035. PubMed ID: 27628534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new kid on the block: Outcomes with Kcentra 1 year after approval.
    Berndtson AE; Huang WT; Box K; Kobayashi L; Godat LN; Smith AM; Weingarten D; Coimbra R
    J Trauma Acute Care Surg; 2015 Dec; 79(6):1004-8. PubMed ID: 26488322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Four-factor prothrombin complex concentrate dose response relationship with INR for warfarin reversal.
    Yohe AS; Livings SE
    Am J Emerg Med; 2019 Aug; 37(8):1534-1538. PubMed ID: 31130370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of 4-factor Prothrombin Complex Concentrate in Patients With Liver Disease and Nonvitamin K Antagonist-Related Coagulopathy: A Retrospective Study.
    Dodhiawala PB; Pribyl K; Larson J; Vakayil V; Chandrashekar M; Lord A; Welbig J; Zantek ND; Martin D; Harmon JV
    Clin Appl Thromb Hemost; 2023; 29():10760296231198038. PubMed ID: 37649304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there a difference in efficacy, safety, and cost-effectiveness between 3-factor and 4-factor prothrombin complex concentrates among trauma patients on oral anticoagulants?
    Mangram A; Oguntodu OF; Dzandu JK; Hollingworth AK; Hall S; Cung C; Rodriguez J; Yusupov I; Barletta JF
    J Crit Care; 2016 Jun; 33():252-6. PubMed ID: 27021851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial.
    Goldstein JN; Refaai MA; Milling TJ; Lewis B; Goldberg-Alberts R; Hug BA; Sarode R
    Lancet; 2015 May; 385(9982):2077-87. PubMed ID: 25728933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study.
    Sarode R; Milling TJ; Refaai MA; Mangione A; Schneider A; Durn BL; Goldstein JN
    Circulation; 2013 Sep; 128(11):1234-43. PubMed ID: 23935011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the safety and efficacy between 3-factor and 4-factor prothrombin complex concentrates for the reversal of warfarin.
    Kuroski JE; Young S
    Am J Emerg Med; 2017 Jun; 35(6):871-874. PubMed ID: 28161220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery: A retrospective evaluation.
    Sin JH; Berger K; Lesch CA
    J Crit Care; 2016 Dec; 36():166-172. PubMed ID: 27546767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of four-factor prothrombin complex concentrate in the reversal of warfarin-induced and nonvitamin K antagonist-related coagulopathy.
    Young H; Holzmacher JL; Amdur R; Gondek S; Sarani B; Schroeder ME
    Blood Coagul Fibrinolysis; 2017 Oct; 28(7):564-569. PubMed ID: 28604569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study.
    Smith MN; Deloney L; Carter C; Weant KA; Eriksson EA
    J Thromb Thrombolysis; 2019 Aug; 48(2):250-255. PubMed ID: 30941571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of 4F-PCC to correct direct oral anticoagulant-induced coagulopathy: An observational analysis.
    Zheng Y; Tormey CA
    Transfus Med; 2020 Aug; 30(4):304-307. PubMed ID: 32342588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of four-factor prothrombin complex concentrate fixed, weight-based dosing for reversal of warfarin anticoagulation.
    Endres K; St Bernard R; Chin-Yee I; Hsia C; Lazo-Langner A
    Hematology; 2020 Dec; 25(1):489-493. PubMed ID: 33317427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thromboembolic Risk of 4-Factor Prothrombin Complex Concentrate versus Fresh Frozen Plasma for Urgent Warfarin Reversal in the Emergency Department.
    Maguire M; Fuh L; Goldstein JN; Marshall AL; Levine M; Howell ML; Parry BA; Rosovsky R; Hayes BD
    West J Emerg Med; 2019 Jul; 20(4):619-625. PubMed ID: 31316701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Use of Kcentra
    Pereira D; Liotta E; Mahmoud AA
    J Pharm Pract; 2018 Feb; 31(1):120-125. PubMed ID: 29278982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and effectiveness of a prothrombin complex concentrate in approved and off-label indications.
    Marcos-Jubilar M; García Erce JA; Martínez-Calle N; Páramo JA; Martínez Virto A; Quintana-Díaz M
    Transfus Med; 2019 Aug; 29(4):268-274. PubMed ID: 31347218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of Warfarin Reversal with Four-Factor Prothrombin Complex Concentrate for Subtherapeutic INR in Intracerebral Hemorrhage.
    Rivosecchi RM; Durkin J; Okonkwo DO; Molyneaux BJ
    Neurocrit Care; 2016 Dec; 25(3):359-364. PubMed ID: 27076286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protocolized warfarin reversal with 4-factor prothrombin complex concentrate versus 3-factor prothrombin complex concentrate with recombinant factor VIIa.
    Barton CA; Hom M; Johnson NB; Case J; Ran R; Schreiber M
    Am J Surg; 2018 May; 215(5):775-779. PubMed ID: 29338845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roles of Four-Factor Prothrombin Complex Concentrate in the Management of Critical Bleeding.
    Tanaka KA; Shettar S; Vandyck K; Shea SM; Abuelkasem E
    Transfus Med Rev; 2021 Oct; 35(4):96-103. PubMed ID: 34551881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective Evaluation of a Fixed-Dose 4-Factor Prothrombin Complex Concentrate Protocol for Urgent Vitamin K Antagonist Reversal.
    Bitonti MT; Rumbarger RL; Absher RK; Curran LM
    J Emerg Med; 2020 Feb; 58(2):324-329. PubMed ID: 31787372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.